KLK3 and prostate adenocarcinoma: The patient’s initial prostate adenocarcinoma was diagnosed in 2017, managed with transurethral resection of the prostate (TURP), radical radiotherapy, and adjuvant hormonal therapy up until 2019, with stable disease and prostate-specific antigen (PSA) until 2024.